Mechanisms of vasodilatation and antivasoconstriction.
D000199:Actins / Q000502:physiology; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000804:Angiotensin II / Q000037:antagonists & inhibitors; D001157:Arterial Occlusive Diseases / Q000628:therapy*; D001920:Bradykinin / Q000378:metabolism; D002118:Calcium / Q000502:physiology*; D002936:Cinnarizine / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D006801:Humans; D009130:Muscle, Smooth / Q000502:physiology; D009218:Myosins / Q000502:physiology; D010208:Papaverine / Q000494:pharmacology; D010879:Piperazines / Q000494:pharmacology; D011453:Prostaglandins / Q000502:physiology; D013806:Theophylline / Q000494:pharmacology; D014661:Vasoconstriction / Q000187:drug effects; D014664:Vasodilation; D003189:p-Methoxy-N-methylphenethylamine / Q000502:physiology
D000199:Actins; D000317:Adrenergic alpha-Antagonists; D010879:Piperazines; D011453:Prostaglandins; D000804:Angiotensin II; D002936:Cinnarizine; D003189:p-Methoxy-N-methylphenethylamine; D013806:Theophylline; D010208:Papaverine; D009218:Myosins; D001920:Bradykinin; D002118:Calcium